SG Americas Securities LLC Increases Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

SG Americas Securities LLC raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 245.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 138,495 shares of the company's stock after buying an additional 98,413 shares during the period. SG Americas Securities LLC owned 0.17% of IDEXX Laboratories worth $58,161,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in IDXX. Silver Oak Securities Incorporated increased its stake in IDEXX Laboratories by 84.0% in the 4th quarter. Silver Oak Securities Incorporated now owns 631 shares of the company's stock valued at $260,000 after buying an additional 288 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of IDEXX Laboratories by 0.5% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 198,450 shares of the company's stock worth $82,047,000 after purchasing an additional 916 shares during the last quarter. Moloney Securities Asset Management LLC acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth about $374,000. Empowered Funds LLC boosted its holdings in shares of IDEXX Laboratories by 10.2% during the 4th quarter. Empowered Funds LLC now owns 1,443 shares of the company's stock worth $597,000 after buying an additional 133 shares during the period. Finally, Entropy Technologies LP boosted its holdings in shares of IDEXX Laboratories by 69.7% during the 4th quarter. Entropy Technologies LP now owns 5,500 shares of the company's stock worth $2,274,000 after buying an additional 2,259 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Stifel Nicolaus boosted their price objective on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a report on Monday, May 19th. Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Morgan Stanley boosted their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Finally, Leerink Partners boosted their price objective on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $546.00.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the transaction, the director now owns 1,801 shares in the company, valued at approximately $922,724.34. This represents a 41.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Trading Down 0.3%

Shares of NASDAQ IDXX traded down $1.46 during mid-day trading on Friday, hitting $525.47. The stock had a trading volume of 134,096 shares, compared to its average volume of 647,729. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $537.00. The business has a 50 day moving average price of $469.88 and a two-hundred day moving average price of $443.57. The firm has a market cap of $42.26 billion, a P/E ratio of 49.25, a price-to-earnings-growth ratio of 3.41 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The firm had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The company's revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.71 EPS. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.